Changes

Line 1: Line 1:  
{{DISPLAYTITLE:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion}}
 
{{DISPLAYTITLE:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion}}
 +
 
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]
 
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]
    
{{Under Construction}}
 
{{Under Construction}}
   −
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1]].
+
<blockquote class="blockedit">{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1]].
 
}}</blockquote>
 
}}</blockquote>
   Line 74: Line 75:       −
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}
    
*May present as a myeloid sarcoma and, if so, the bone marrow aspirate blast count may be misleadingly low
 
*May present as a myeloid sarcoma and, if so, the bone marrow aspirate blast count may be misleadingly low
Line 142: Line 143:  
 
   −
<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
 
|-
 
|-
Line 157: Line 158:       −
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
+
<blockquote class="blockedit">{{Box-round|title=v4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).|Please incorporate this section into the relevant tables found in:
 
* Chromosomal Rearrangements (Gene Fusions)
 
* Chromosomal Rearrangements (Gene Fusions)
 
* Individual Region Genomic Gain/Loss/LOH
 
* Individual Region Genomic Gain/Loss/LOH
Line 227: Line 228:  
|}
 
|}
   −
<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}
    
9q22 loss
 
9q22 loss
Line 255: Line 256:  
|}
 
|}
   −
<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
    
Additional aberrations in >70% of cases with t(8;21); common loss of a sex chromosome or deletion 9q
 
Additional aberrations in >70% of cases with t(8;21); common loss of a sex chromosome or deletion 9q
 +
 +
Trisomy 4 is a rare numerical abnormality detected in 3% of AML patients with t(8;21) (PMIDs: 12682630, 26573082, 27451976). A negative effect on prognosis this group of patients has been attributed to the presence of the mutations in the KIT gene.. Gain of chromosome 4 would likely result in increased dosage of the mutant KIT allele (PMIDs: 16291592, 30899636).
    
</blockquote>
 
</blockquote>
Line 294: Line 297:       −
<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}
    
AML with t(8;21)(q22;q22) has genetic heterogeneity at the molecular level.  Several genes have been identified that are frequently mutated in this subset of AML, some of them adversely affecting prognosis.
 
AML with t(8;21)(q22;q22) has genetic heterogeneity at the molecular level.  Several genes have been identified that are frequently mutated in this subset of AML, some of them adversely affecting prognosis.
Line 352: Line 355:  
|}
 
|}
   −
<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
+
<blockquote class="blockedit">{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
    
Genes:
 
Genes:
Line 411: Line 414:  
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
 
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
   −
'''
+
<br />
    
==Notes==
 
==Notes==
Line 419: Line 422:     
<nowiki>*</nowiki>''Citation of this Page'': “Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Acute_myeloid_leukaemia_with_RUNX1::RUNX1T1_fusion</nowiki>.
 
<nowiki>*</nowiki>''Citation of this Page'': “Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Acute_myeloid_leukaemia_with_RUNX1::RUNX1T1_fusion</nowiki>.
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases A]]
+
[[Category:HAEM5]]
 +
[[Category:DISEASE]]
 +
[[Category:Diseases A]]